SPR Therapeutics
PrivateLast Round
M&A
Jul 16, 2026
Est. Valuation
$650M
Total Funding Raised
$108.4M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
SPR Therapeutics operates in Healthcare & Life Sciences and is based in Cleveland, Ohio. Its latest recorded funding round was a Series D Extension round in February 2024.
SPR Therapeutics is a medical device company that develops and commercializes non-opioid, minimally invasive peripheral nerve stimulation therapy platforms for the management of acute and chronic pain.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SPR Therapeutics Comparables
Compare SPR Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Curonix | 85% | |
| Neuros Medical | 82% | |
| Cortex, Inc. | 81% |
For institutional investors. Book with your work email.
SPR Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Jul 16, 2026 | ||||
| Series D Extension | Feb 1, 2024 | ||||
| Series D | Oct 18, 2021 | ||||
| Grant | Oct 2, 2018 | ||||
| Series C | Sep 12, 2017 | ||||
Convertible Debt | Aug 25, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
SPR Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Serial Stage Venture Partners | Series D |
| SLR Capital Partners | Series D Extension |
| Ohio Third Frontier Commission | Debt |
| JumpStart Ventures | Series A, Pre Seed |
| Mutual Capital Partners | Series D, Series D Extension |
| U.S. Department of Defense | Grant |
| NDI Healthcare Fund | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 16, 2026
$650M round led by Medtronic.
- Apr 20, 2026
Monthly visitors increased 52% MoM.
For institutional investors. Book with your work email.
SPR Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about SPR Therapeutics's valuation, stock price, and market status.
Is SPR Therapeutics a public or private company?
SPR Therapeutics is a private company.
What is the current stock price of SPR Therapeutics?
SPR Therapeutics is a private company, so its shares have no public market price. Caplight tracks SPR Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is SPR Therapeutics worth (valuation)?
SPR Therapeutics's valuation is estimated at $650.0M based on funding round data.
Can I buy SPR Therapeutics stock?
SPR Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was SPR Therapeutics's last funding round?
SPR Therapeutics's most recent funding round was M&A on July 16, 2026.
Who are the main investors in SPR Therapeutics?
Key investors in SPR Therapeutics include SLR Capital Partners, Ohio Third Frontier Commission, JumpStart Ventures, NDI Healthcare Fund, RC Capital.
Will SPR Therapeutics IPO soon?
No public IPO plans have been announced for SPR Therapeutics.
How can I track SPR Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in SPR Therapeutics's shares on secondary markets.